Chandler Chicco Companies Announces New York ... - BioPortfolio

Chandler Chicco Companies Announces New York Leadership Additions to Support
Continued Growth
NEW YORK, March 30, 2012 /PRNewswire/ -- Chandler Chicco Companies (CCC), a global health
communications group and part of inVentiv Health, Inc., announced today the appointment of two
highly-accomplished industry executives to leadership roles in its New York offices, taking full advantage of
opportunities on the horizon.
(Photo: http://photos.prnewswire.com/prnh/20120330/LA79371-a)
(Photo: http://photos.prnewswire.com/prnh/20120330/LA79371-b)
"Chandler Chicco Companies' opportunities, with new and existing clients, continue to increase," said Bob
Chandler, principal of Chandler Chicco Companies and Senior Vice President of Marketing and
Communications for inVentiv Health. "We're fortunate that the Chandler Chicco brand continues to have
'go-to' status in key markets globally. I am confident we will be even more formidable in the coming years."
To help lead the organization through this period of growth, Chandler announced that Jeanine O'Kane has
joined as Managing Director of Biosector 2 (B2) New York. She will take over for Lisa Stockman, who
immediately becomes Managing Director of CCC New York, a newly-created role. Stockman will report
directly to Chandler.
O'Kane joins the firm after more than 20 years of healthcare experience. Most recently she ran the
Healthcare Group for North America at MSLGroup, driving significant growth with notable clients. Prior to
MSLGroup, she served for five years as Director, New York Healthcare Practice and Executive Vice
President at Ogilvy Public Relations. "Jeanine's significant and varied background will assure that B2 remains
as vibrant and successful as it has been over the past several years," Chandler said.
Stockman, who has been with Chandler Chicco Companies since its inception, has directed numerous
Page 1/4

award-winning campaigns, including PRWeek's "Healthcare Campaign of the Year." As head of Biosector 2,
she was responsible for significant year-on-year growth. Before taking over the reins at B2, Stockman led
CCC accounts that included Celebrex, Zoloft and Boniva.
"Working with Lisa over many years I have the highest degree of confidence she will succeed in this new
role," Chandler said. "I couldn't be more confident about our future prospects, and much of that confidence is
due to the brilliance of professionals such as Jeanine and Lisa who think, lead and instinctively know what
has to happen next," Chandler added.
About Chandler Chicco CompaniesChandler Chicco Companies (CCC) is a global health communications
group that delivers unmatched perspective and creative know-how. With an integrated approach to
communications, CCC offers best-in-class capabilities spanning public relations, digital and social media,
medical and scientific education, marketing and branding, graphic design and multimedia, event production
and research and measurement. Companies under the Chandler Chicco umbrella include: Allidura
Consumer, Brandtectonics, Biosector 2, Chamberlain Healthcare Public Relations, Chandler Chicco Agency,
Chandler Chicco Productions, Determinus, Haas & Health Partner Public Relations, Ingenda
Communications, Litmus Medical Marketing & Education, 'nition Design, SanCom Creative Communication
Solutions (CCS), SharedVoice PR and VerStone Digital.
CCC is part of inVentiv Health, Inc., with companies based in New York, Los Angeles, Washington, D.C.,
London, Paris and Eltville (Frankfurt), as well as a global healthcare network operating in 40 markets. For
more information, visit www.chandlerchiccocompanies.com.
About inVentiv HealthinVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial
and consulting services to companies seeking to accelerate performance. inVentiv's client roster includes
more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries,
inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by
inVentiv Group Holdings Inc., an organisation sponsored by affiliates of Thomas H. Lee Partners, L.P.,
Liberty Lane Partners and members of the inVentiv management team. For more information, visit
www.inventivhealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our
Page 2/4

performance to differ materially. These forward-looking statements reflect our current views about future
events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain
important factors may have affected and could in the future affect our actual results and could cause actual
results to differ significantly from those expressed in any forward-looking statement. Such factors include,
without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash
to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the
impact of the consummation of any announced and future acquisitions, and any additional leverage we may
incur in connection with the financing thereof, on our ratings and the ratings of our debt securities; our ability
to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to
permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior
secured credit facilities and to access sufficient capital under our credit agreement or from other sources of
debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our
ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability
to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing
pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the
reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new
clients and cross-sell our services; the potential impact of financial, economic, political and other risks,
including interest rate and exchange rate risks, related to conducting business internationally; our ability to
successfully operate new lines of business; our ability to manage our infrastructure and resources to support
our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations
and integrate the acquired businesses into our operation, and the resulting synergies; the resolution of
purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any
disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may
adversely impact our continued investment in and development of software; the potential impact of
government regulation on us and on our client base; our ability to comply with all applicable laws as well as
our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our
ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that
client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible
assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical
industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer
internally; the impact of customer project delays and cancellations; the potential liability associated with
bringing new drugs to market, including potential liability from injury to clinical trial participants; the actual
impact of the adoption of certain accounting standards; and our ability to maintain technological advantages
Page 3/4

in a variety of functional areas, including sales force automation, electronic claims surveillance and patient
compliance. Holders of our debt instruments are referred to reports provided to investors from time to time
and the offering memorandums provided in connection with the issuance of our senior secured notes for
further discussion of these risks and other factors.
SOURCE Chandler Chicco Companies
http://www.bioportfolio.com/news/article/998119/Chandler-Chicco-Companies-Announces-New-York-Leadership-Additions-To-Suppor
t-Continued-Growth.html
Page 4/4